Nyxoah SA (NYXH): Next-Year EPS Estimate 38.36%
As of 2026-11-12, Nyxoah SA (NYXH) has a next-year EPS growth estimate of 38.36%. Featured in 2 EPS revision reports, most recently on 2026-08-14.
On 2026-11-12, analyst consensus for NYXH's next-year EPS growth shifted from 38.35% to 38.36% — a positive change of 0.01 percentage points. Current-year growth is projected at 56.12%.
What's Driving This
Nyxoah’s primary structural driver is a marginal analyst revision: next-year EPS growth was raised 0.01 pp to 37.71% on 2026-10-15. The current estimate has since eased to 37.68%, so there is no clear continued upward momentum beyond the initial revision. Headlines offer plausible operational catalysts, including Q2 2026 US revenue rising 22% sequentially, full 12-month ACCCESS data, and a CEO appointment, but none explicitly explains the
Generated 2026-10-22 from news as of 2026-10-21
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Devices
- EPS growth next year
- 38.36%
- EPS growth this year
- 56.12%
- EPS next quarter (est)
- -$0.20
- Last price
- $0.90
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 38.36% | 56.12% | -$0.20 | $0.90 |
| 2026-11-11 | 38.35% | 56.09% | -$0.20 | $0.90 |
| 2026-11-10 | 38.35% | 56.09% | -$0.20 | $0.90 |
| 2026-11-09 | 38.35% | 56.09% | -$0.20 | $0.89 |
| 2026-11-07 | 38.35% | 56.09% | -$0.20 | $0.85 |
| 2026-11-06 | 38.35% | 56.09% | -$0.20 | $0.85 |
| 2026-11-05 | 37.74% | 51.91% | -$0.35 | $0.81 |
| 2026-11-04 | 37.74% | 51.91% | -$0.35 | $0.86 |
| 2026-11-03 | 37.74% | 51.91% | -$0.35 | $0.87 |
| 2026-11-02 | 37.74% | 51.91% | -$0.35 | $0.88 |
| 2026-10-31 | 37.74% | 51.91% | -$0.35 | $0.87 |
| 2026-10-30 | 37.74% | 51.91% | -$0.35 | $0.87 |
| 2026-10-29 | 37.74% | 51.91% | -$0.35 | $0.89 |
| 2026-10-28 | 37.74% | 51.91% | -$0.35 | $0.90 |
| 2026-10-27 | 37.74% | 51.91% | -$0.35 | $0.91 |
| 2026-10-26 | 37.74% | 51.91% | -$0.35 | $0.86 |
| 2026-10-23 | 37.68% | 52.23% | -$0.35 | $0.83 |
| 2026-10-22 | 37.68% | 52.23% | -$0.35 | $0.82 |
| 2026-10-21 | 37.68% | 52.23% | -$0.35 | $0.89 |
| 2026-10-20 | 37.68% | 52.23% | -$0.35 | $0.94 |
| 2026-10-19 | 37.22% | 52.69% | -$0.35 | $0.95 |
| 2026-10-16 | 37.25% | 52.62% | -$0.35 | $1.11 |
| 2026-10-15 | 37.71% | 52.61% | -$0.35 | $1.19 |
| 2026-10-14 | 37.70% | 52.44% | -$0.35 | $1.25 |
| 2026-10-13 | 37.70% | 52.44% | -$0.35 | $1.28 |
| 2026-10-12 | 37.70% | 52.44% | -$0.35 | $1.31 |
| 2026-10-11 | 37.70% | 52.44% | -$0.35 | $1.36 |
| 2026-10-10 | 37.70% | 52.44% | -$0.35 | $1.36 |
| 2026-10-09 | 37.70% | 52.44% | -$0.35 | $1.36 |
| 2026-10-08 | 37.70% | 52.44% | -$0.35 | $1.35 |
Reports Featuring NYXH
Recent News
- Nyxoah Narrows Its Loss And Accelerates U.S. Growth, But The Ramp Is Slower Than Promised And Leading Indicators Are CoolingEarnings Whispers
- Nyxoah Reports Third Quarter 2026 Financial and Operating ResultsGlobeNewswire
- Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026GlobeNewswire
- Nyxoah Appoints Liam Kelly as Chief Executive OfficerGlobeNewswire
- CVRx names John Landry as CFOMedTech Dive
- Nyxoah SA (NYXH) (Q2 2026) Earnings Call Highlights: US Revenue Surges 22% Sequentially, $110M ...GuruFocus.com
- Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating ResultsGlobeNewswire
- Nyxoah to Host Investor Day in New York on July 8, 2026GlobeNewswire
- Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 9, 2026GlobeNewswire
- Publication relating to transparency notificationsGlobeNewswire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Nyxoah SA's next-year EPS growth estimate?▾
As of 2026-11-12, Nyxoah SA (NYXH) has a next-year EPS growth estimate of 38.36%, based on analyst consensus.
When was the latest EPS estimate revision for NYXH?▾
The most recent revision occurred on 2026-11-12, when analysts adjusted the next-year EPS growth estimate from 38.35% to 38.36%.
What sector and industry does Nyxoah SA belong to?▾
Nyxoah SA operates in the Healthcare sector, specifically the Medical Devices industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. NYXH appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Nyxoah SA (NYXH) appears here because it was detected by our daily top-EPS-revision-performer screen.